| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00173-0847-61 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Jun 10, 2013 | Dec 11, 2014 | No Longer Used |
| 23155-0774-71 | 23155-0774 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 15, 2022 | Jun 15, 2022 | No Longer Used |
| 00703-4154-91 | 00703-4154 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Oct 1, 2002 | Dec 31, 2012 | In Use |
| 67184-0607-01 | 67184-0607 | HYDROXYUREA | HYDROXYUREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Mar 6, 2024 | In Use | |
| 00703-4239-01 | 00703-4239 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Oct 23, 2014 | In Use | |
| 65162-0794-09 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
| 69945-0450-03 | 69945-0450 | sodium iodide, i-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 64842-1020-02 | 64842-1020 | Trifluridine and Tipiracil | Lonsurf | 8.19 mg/1, 20.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Nov 11, 2015 | In Use | |
| 59923-0725-30 | 59923-0725 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 1, 2020 | In Use | |
| 55150-0271-01 | 55150-0271 | Cyclophosphamide | Cyclophosphamide | 1.0 g/5mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Aug 25, 2021 | In Use | |
| 71288-0100-51 | 71288-0100 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 19, 2017 | In Use | |
| 68001-0342-34 | 68001-0342 | GEMCITABINE | GEMCITABINE | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 25, 2018 | In Use | |
| 80005-0116-02 | 80005-0116 | LOMUSTINE | LOMUSTINE | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Nov 10, 2025 | In Use | |
| 71288-0165-54 | 71288-0165 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Jan 10, 2023 | In Use | |
| 67457-0937-50 | 67457-0937 | PACLITAXEL | PACLITAXEL | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 9, 2025 | In Use | |
| 00069-0151-11 | 00069-0151 | Axitinib | Inlyta | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 27, 2012 | In Use | |
| 42806-0903-26 | 42806-0903 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jun 30, 2024 | In Use | |
| 80005-0114-02 | 80005-0114 | LOMUSTINE | LOMUSTINE | 10.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Nov 10, 2025 | In Use | |
| 00085-1417-02 | 00085-1417 | Temozolomide | Temodar | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
| 00310-0640-60 | 00310-0640 | SELUMETINIB | KOSELUGO | 7.5 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | Sep 10, 2025 | In Use | |
| 73150-0200-12 | 73150-0200 | umbralisib | UKONIQ | 260.2 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Oral | Feb 5, 2021 | Jul 31, 2023 | No Longer Used |
| 69784-0610-25 | 69784-0610 | Chlorambucil | LEUKERAN | 2.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | Jun 30, 2022 | In Use | |
| 00093-7639-57 | 00093-7639 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | Jul 31, 2019 | In Use |
| 00115-1675-72 | 00115-1675 | Epirubicin Hydrochloride | Epirubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Sep 21, 2016 | Apr 3, 2019 | In Use |
| 67457-0467-21 | 67457-0467 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | Mar 30, 2012 | Mar 31, 2016 | No Longer Used |
Found 12159 results — Export these results
Home